DE3045990C2 - Verfahren zur Reinigung von Teilchen biologischen Ursprungs - Google Patents
Verfahren zur Reinigung von Teilchen biologischen UrsprungsInfo
- Publication number
- DE3045990C2 DE3045990C2 DE3045990A DE3045990A DE3045990C2 DE 3045990 C2 DE3045990 C2 DE 3045990C2 DE 3045990 A DE3045990 A DE 3045990A DE 3045990 A DE3045990 A DE 3045990A DE 3045990 C2 DE3045990 C2 DE 3045990C2
- Authority
- DE
- Germany
- Prior art keywords
- particles
- rotor
- centrifugation
- antigen
- speed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002245 particle Substances 0.000 title claims description 67
- 238000000034 method Methods 0.000 title claims description 35
- 230000008569 process Effects 0.000 title claims description 10
- 238000000746 purification Methods 0.000 title claims description 9
- 238000005119 centrifugation Methods 0.000 claims description 44
- 239000000427 antigen Substances 0.000 claims description 40
- 102000036639 antigens Human genes 0.000 claims description 40
- 108091007433 antigens Proteins 0.000 claims description 40
- 238000005194 fractionation Methods 0.000 claims description 18
- 239000000725 suspension Substances 0.000 claims description 18
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims description 17
- 238000004062 sedimentation Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 description 37
- 239000012535 impurity Substances 0.000 description 19
- 239000007788 liquid Substances 0.000 description 16
- 239000000463 material Substances 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 12
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 9
- 238000001738 isopycnic centrifugation Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000004140 cleaning Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102000004895 Lipoproteins Human genes 0.000 description 6
- 108090001030 Lipoproteins Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000007212 Foot-and-Mouth Disease Diseases 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011538 cleaning material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Centrifugal Separators (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7930135A FR2470795A1 (fr) | 1979-12-07 | 1979-12-07 | Procede de purification de particules d'origine biologique, notamment de l'antigene de surface du virus de l'hepatite b (aghbs) et les produits obtenus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3045990A1 DE3045990A1 (de) | 1981-09-03 |
| DE3045990C2 true DE3045990C2 (de) | 1985-08-22 |
Family
ID=9232533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3045990A Expired DE3045990C2 (de) | 1979-12-07 | 1980-12-05 | Verfahren zur Reinigung von Teilchen biologischen Ursprungs |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4335214A (cg-RX-API-DMAC10.html) |
| JP (1) | JPS5692219A (cg-RX-API-DMAC10.html) |
| DE (1) | DE3045990C2 (cg-RX-API-DMAC10.html) |
| FR (1) | FR2470795A1 (cg-RX-API-DMAC10.html) |
| GB (1) | GB2064322B (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59101426A (ja) * | 1982-11-29 | 1984-06-12 | Green Cross Corp:The | Ｂ型肝炎感染予防用ワクチンの製造方法 |
| FR2561256B1 (fr) * | 1984-03-16 | 1987-01-02 | Pasteur Institut | Procede de purification de particules biologiques de type antigene hbs, par ultracentrifugation de flottation sur gradient de densite |
| US4683294A (en) * | 1985-04-03 | 1987-07-28 | Smith Kline Rit, S.A. | Process for the extraction and purification of proteins from culture media producing them |
| FR2632308B1 (fr) * | 1988-06-07 | 1991-08-16 | Fondation Nale Transfusion San | Procede et installation de fractionnement en continu de proteines vegetales animales ou humaines |
| US5462863A (en) * | 1989-02-09 | 1995-10-31 | Development Center For Biotechnology | Isolation of Hepatitis B surface antigen from transformed yeast cells |
| CN113583801A (zh) * | 2020-04-30 | 2021-11-02 | 上海青赛生物科技有限公司 | 一种病毒密度梯度离心纯化装置 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2150559A1 (en) * | 1971-06-09 | 1973-04-13 | Merieux Inst | Australia antigen purification - for preparation of purified suspensions |
| GB1356413A (en) * | 1971-09-09 | 1974-06-12 | Pfizer Ltd | Method of obtaining purified australia antigen from blood serum |
| GB1486557A (en) * | 1973-10-18 | 1977-09-21 | Flockhart & Co | Process for the preparation of pyrogen-free sub-unit vaccine |
| US3951937A (en) * | 1973-12-20 | 1976-04-20 | The Community Blood Council Of Greater New York, Inc. | Large scale purification of hepatitis type B antigen using polyethylene glycol |
| US4017360A (en) * | 1975-05-14 | 1977-04-12 | Merck & Co., Inc. | Method for purifying hepatitis B antigen |
| US4024243A (en) * | 1975-06-16 | 1977-05-17 | Merck & Co., Inc. | Process for isolating hepatitis B antigen |
| FR2338051A1 (fr) * | 1976-01-19 | 1977-08-12 | Community Blood Council Greate | Procede de preparation d'antigene d'hepatite b purifie et produits obtenus |
| US4088748A (en) * | 1976-11-02 | 1978-05-09 | Merck & Co., Inc. | Hepatitis B surface antigen |
| US4118477A (en) * | 1977-02-14 | 1978-10-03 | Merck & Co., Inc. | Hepatitis B antigen |
| GB1554812A (en) * | 1977-02-23 | 1979-10-31 | Merck & Co Inc | Purifying hepatitis b surface antigen |
| FR2412315A1 (fr) * | 1977-02-23 | 1979-07-20 | Merck & Co Inc | Procede de preparation d'un antigene de l'hepatite b et l'antigene obtenu |
| GB1554811A (en) * | 1977-02-23 | 1979-10-31 | Merck & Co Inc | Purifying hepatitis b surface antigen |
| US4102996A (en) * | 1977-04-20 | 1978-07-25 | Merck & Co., Inc. | Method of preparing hepatitis B core antigen |
| JPS54101421A (en) * | 1978-01-27 | 1979-08-10 | Merck & Co Inc | Hepatitis b surface antigen |
| FR2415639A1 (fr) * | 1978-01-27 | 1979-08-24 | Merck & Co Inc | Antigene de surface de l'hepatite b |
| DE2803920A1 (de) * | 1978-01-30 | 1979-08-02 | Merck & Co Inc | Verfahren zur gewinnung von hepatitis b-oberflaechenantigen |
| DK187679A (da) * | 1978-05-08 | 1979-11-09 | Merck & Co Inc | Fremgangsmaade til direkte ekstraktion af smaa partikler fra en proteinholdig vaeske |
| US4217418A (en) * | 1978-05-08 | 1980-08-12 | Merck & Co., Inc. | Recovery of small particles by flow centrifugation |
| US4204989A (en) * | 1978-12-13 | 1980-05-27 | Merck & Co., Inc. | Isolation of hepatitis B e antigen |
-
1979
- 1979-12-07 FR FR7930135A patent/FR2470795A1/fr active Granted
-
1980
- 1980-12-05 US US06/213,315 patent/US4335214A/en not_active Expired - Lifetime
- 1980-12-05 JP JP17192480A patent/JPS5692219A/ja active Granted
- 1980-12-05 GB GB8039069A patent/GB2064322B/en not_active Expired
- 1980-12-05 DE DE3045990A patent/DE3045990C2/de not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| NICHTS-ERMITTELT |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0133157B2 (cg-RX-API-DMAC10.html) | 1989-07-12 |
| FR2470795A1 (fr) | 1981-06-12 |
| US4335214A (en) | 1982-06-15 |
| GB2064322A (en) | 1981-06-17 |
| DE3045990A1 (de) | 1981-09-03 |
| FR2470795B1 (cg-RX-API-DMAC10.html) | 1983-07-01 |
| JPS5692219A (en) | 1981-07-25 |
| GB2064322B (en) | 1983-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69323621T2 (de) | Vorrichtung und verfahren zur gewinnung von leukocytfreiem trombozytkonzentrat | |
| EP0530688B1 (de) | Verfahren und Vorrichtung zum Trennen von Blut in seine Bestandteile | |
| DE69032246T2 (de) | Filtration von Blutplättchen vor der Lagerung | |
| DE69425893T2 (de) | Beutelsatz zur verwendung bei trennschleudern | |
| DE69926313T2 (de) | Verfahren zum separieren von partikeln | |
| DE69115648T2 (de) | Trennungssystem im Boden von Blutbeuteln | |
| DE19802321C2 (de) | Verfahren und Vorrichtung zur Aufbereitung von intra- oder postoperativen Blutverlusten für die Autotransfusion | |
| DE3036220A1 (de) | Verfahren bei und vorrichtung zur untersuchung von nicht geronnenem blut | |
| DE1769289A1 (de) | Verfahren und Vorrichtung zum Ausziehen eines Tochterradioisotops aus einem Mutterradioisotop | |
| DE3112539A1 (de) | Verfahren zur auftrennung von waessrigen proteingemischen | |
| DE2747496A1 (de) | Verfahren und vorrichtung zur bestimmung pathogener mikroorganismen | |
| DE102009022605B4 (de) | Verfahren und Vorrichtung zum Auftrennen von Vollblut | |
| DE3045990C2 (de) | Verfahren zur Reinigung von Teilchen biologischen Ursprungs | |
| DE69932151T2 (de) | Verfahren und vorrichtung zum transformieren von plasma | |
| EP3096811A1 (de) | Vorrichtung zur trennung von blut in seine bestandteile sowie verfahren hierzu und verwendung einer solchen vorrichtung | |
| DE2653879A1 (de) | Verfahren und vorrichtung zur abtrennung von macro-molekuelen aus fluessigen substanzen | |
| EP1073487B1 (de) | Verfahren zur herstellung eines thrombozytenpräparates | |
| EP2683250B1 (de) | Verfahren zur gewinnung eines inhaltsstoffes aus molkenproteinkonzentrat | |
| DE68902058T2 (de) | Verfahren zur extrakorporalen behandlung von ascites-fluessigkeit. | |
| DE2748520C2 (cg-RX-API-DMAC10.html) | ||
| CH644271A5 (de) | Verfahren zur herstellung von fruehsommer-meningoenzephalitis-virus-vakzinen. | |
| DE2047704C3 (cg-RX-API-DMAC10.html) | ||
| DE69920209T2 (de) | Verfahren zur kontinuierlichen reinigung und konzentrierung von leukozyten aus dem blut | |
| DE2709581C2 (cg-RX-API-DMAC10.html) | ||
| DE2415079A1 (de) | Verfahren zur isolierung von albumin aus blut |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |